| Document |
Document Title |
|
WO/1990/010023A1 |
A copolymer of an N-acylated glycosylamine and an amide having general formula (I), wherein R2 is a reducing sugar residue; R3 is H or CH3; x is an integer from 0 to about 20; and m is such that the molecular weight of the copolymer is f...
|
|
WO/1990/008549A1 |
N-acetylglucosamine preparations for oral administration, used to treat degenerative and inflammatory diseases of the articulations and of the connective tissue and stroma, and related diseases.
|
|
WO/1990/002132A1 |
Constituents of the non-protein-nitrogen fraction of untreated raw milk or fresh milk have a characteristic pharmacological activity.
|
|
WO/1989/010373A1 |
Chemical compounds characterized by formula (I) wherein R1 is hydrogen or optionally substituted alkyl, R2 is hydrogen, and optionally substituted alkyl or a radical derived from the hydroxyl function and n is comprised between 0 and 7 p...
|
|
WO/1989/008845A1 |
Antibodies, specific for N-glycane structures of cell membrane surfaces and which, in an immunoassay, for example RIA and ELISA assay, or microtiter plates, exhibit a positive reaction to antigen oligosaccharides with structural elements...
|
|
WO/1989/007602A1 |
Anion exchange resins which have been exchanged with molybdate at acid pH are effective catalysts for epimerizing compounds with structural unit (I). Chief among these are aldoses, especially aldopentoses and aldohexoses, as well as some...
|
|
WO/1989/003672A1 |
The invention concerns a drug for preventing gram-negative bacillary infections and mycoses in patients at risk, comprising the association of three antibiotics: polymyxin B, netilmycin and amphotericin B, administered by precise sprayin...
|
|
WO/1989/003673A1 |
The invention concerns a drug for preventing gram-negative bacillary infections and mycoses in patients at risk, comprising the association of three antibiotics: polymyxin B, tobramycin and amphoterycin B, administered by precise sprayin...
|
|
WO/1988/004323A1 |
A method for preparing a 1-amino-1-deoxyoligosaccharide comprising reacting, at a pH of at least 6.5, a glycopeptide or glycoprotein containing one or more Asn-linked oligosaccharides with a beta-aspartylglycosylamine amidohydrolase.
|
|
WO/1987/005905A1 |
Novel 5-deoxy-5-fluoromethylthioribose derivatives represented by formula (I), (wherein R represents CF2H or CFH2) and a pharmaceutical composition containing the novel compound of formula (I). The compounds are useful as physiologically...
|
|
WO/1986/001502A1 |
A process for the production of amino compounds from hydroxyl compounds (Voelter reaction), according to which a hydroxyl compound is converted with trifluormethanesulphonic acid anhydride in water-free conditions, the corresponding trif...
|
|
WO/1985/004881A1 |
Compounds of formula (I) wherein R2 and R3 are the same or different and each represent unsubstituted or substituted acyl, and a) R1 represents lower alkyl, aralkyl or the phosphate, pyrophosphate, phosphorylethanolamine or pyrophosphory...
|
|
WO/1984/003302A1 |
Hyaluronic acid, a polysaccharide, is prepared in high yield from streptococcus bacteria by fermenting the bacteria under anaerobic conditions in a CO2-enriched growth medium, separating the bacteria from the resulting broth and isolatin...
|
|
WO/1984/001896A1 |
Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)-phenyl-alpha-D-gluco- and mannopyranosides, p-(glutarylamido)-phhenyl-alpha-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-alpha-D-gluco- and mannopyranosides ...
|
|
WO/1983/001706A1 |
A telecommunication cable C, and method of making same, comprised of more than five S-Z twisted wire pairs (10) having their twist reversals (20) longitudinally staggered in a repetitive sequence of 1 to N longitudinally spaced positions...
|
|
WO/1979/001068A1 |
Novel arabinofuranosyl nucleosides and nucleotides having 2'-azido, 2'-amino, or 2'-hydrocarbylamino substituents, which have antitumor, antiviral, and antimicrobial properties, are prepared by condensation of a pyrimidine, purine, or 1,...
|
|
JP2024041834A |
[Problem] Novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, as well as sepsis, toxemia, septic shock, ocular infections, ocular inflammation, ocular neovascularization, rheumatoid arthritis (RA). , atheros...
|
|
JP7455802B2 |
The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.
|
|
JP2024510267A |
Fibroblast activation protein (FAP) targeting compounds; methods of imaging cancer and fibrosis; and methods of treating fibrosis, inflammatory diseases/disorders and cancer.
|
|
JP2024506398A |
The invention features compounds and methods of treating injuries or diseases (eg, stroke, congenital hypogonadotropic hypogonadism, viral infections) using the compounds. The invention also features pharmaceutical compositions that incl...
|
|
JP2024019400A |
An object of the present invention is to provide a carbohydrate-conjugated iRNA agent that is advantageous for in vivo delivery of the iRNA agent. The present invention makes it possible to provide carbohydrate-conjugated iRNA agents tha...
|
|
JP2024014933A |
The present invention provides compounds for use in the prevention or treatment of joint and bone disorders, such as arthritis and osteoporosis, in mammals. [Solution] Formula (A) [C1] The above-mentioned problems are solved by the compo...
|
|
JP2023553939A |
The present invention relates to the pentose intermediate of fondaparinux sodium, and is based on an automated device to realize automated production of the three components (D+EF+GH) through automatic sample loading, automatic sampling ...
|
|
JP2023549503A |
The present disclosure provides a method of treating or preventing, or delaying the onset or progression of, an amyloidogenic disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comp...
|
|
JP7376999B2 |
The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin.In particular, the present invention relates to N-palmitoyl-D-glucosamine in a micronized or co...
|
|
JP2023154006A |
To provide a medicament for the treatment or prophylaxis of diseases involved mainly with the regulation of the turnover of macromolecules that make up the extracellular matrix of cartilage tissue.Provided is an amino acid derivative of ...
|
|
JP2023542455A |
The present invention provides compounds represented by general formula I, stereoisomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable esters thereof, pharmaceutically acceptable hydrates thereof, or pha...
|
|
JP2023541497A |
In the present invention, there is no phosphate group at the C1 position of the reducing end of the lipid A domain, and it is substituted by a hydrophilic moiety at the C6' position of the non-reducing end of the lipid A domain, provided...
|
|
JP2023541007A |
The present disclosure relates to acute respiratory distress syndrome (ARDS) associated with viral infections caused by influenza, rhinoviruses or human coronaviruses, including beta coronavirus infections such as SARS coronavirus, MERS ...
|
|
JP7319405B2 |
|
|
JP7295571B2 |
The cell labeling agent includes a monosaccharide derivatives with a six-membered ring structure that are metabolized to sialic acid in the sialic acid biosynthetic pathway of cells. Among the groups bonded to carbon atoms constituting a...
|
|
JP2023519952A |
The present invention provides the formula (X) [Chemical 1] The method is suitable for large-scale synthesis.
|
|
JP2023063994A |
To provide a compound that can serve as a primer for elongation of O-mannosyl glycan sugar chains associated with muscular dystrophy, a composition thereof and a production method therefor, and a sugar chain elongation method using the s...
|
|
JP7261850B2 |
The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof.
|
|
JP2023511756A |
Compounds with asialoglycoprotein receptor (ASGPR) binding ligands linked to extracellular protein-binding ligands that selectively degrade target extracellular proteins in vivo to treat disorders mediated by extracellular proteins and c...
|
|
JP2023025162A |
To provide modulators of the TGR5 receptor useful in the treatment of TGR5-mediated diseases or disorders.The present invention provides non-systemic TGR5 agonists having the following formula. Specifically, an example of such agonists i...
|
|
JP2023021979A |
To provide compounds and methods for treating RNA mediated diseases.The invention provides a compound, a composition thereof and a method for using the same, which is: a compound of Formula I or pharmaceutically acceptable salt thereof w...
|
|
JP2023506066A |
The present invention relates to the formula (I) [Chemical 1] (I) The method is suitable for large-scale synthesis.
|
|
JP7210771B2 |
A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 inhibitor-related diseases. Specifically disclosed is a derivative compound represented by formula (II), a tautomer ...
|
|
JP2023501682A |
The present invention relates to a method for drying human milk oligosaccharides (HMO). More particularly, the present invention relates to a method for roller or drum drying human milk oligosaccharides in a simple and economical manner....
|
|
JP2023500396A |
Disclosed herein are tucaresol derivative compounds and compositions comprising the same. Also disclosed herein are methods of enhancing an immune response in a subject by administering a tucaresol derivative compound or by co-administer...
|
|
JP7198482B2 |
To provide a compound for endo-β-N-acetylglucosaminidase activity detection.The present invention provides a compound expressed by a formula I in which a combination of a fluorescent group and an extinction group causing fluorescence re...
|
|
JP7198919B2 |
An atomizing liquid gel with reversible phase transition characteristics includes: a sugar-based gelling agent, 0.1-3.0 wt%; an atomizing agent, 97.0-99.9 wt%; a molecule of the sugar-based gelling agent is a sugar molecule introduced wi...
|
|
JP2022181211A |
To provide compounds useful for detection of amyloid or amyloid like proteins, methods for detecting the proteins, and methods for treating diseases associated with the proteins.For example, following compounds are illustrated.SELECTED D...
|
|
JP2022545101A |
The present disclosure relates to GalNAc moieties comprising at least one GalNAc monomer. The present disclosure also relates to GalNAc-oligonucleotide conjugates comprising a GalNAc portion and an oligonucleotide, eg, saRNA or siRNA, us...
|
|
JP2022542118A |
The present invention relates to 6-azido-6-deoxy-2-N-acetyl-monosaccharide-nucleoside diphosphates, in particular 6-azido-6-deoxy-2-N-acetyl-D-galactosamine-nucleoside diphosphates or It relates to a method for synthesizing 6-azido-6-deo...
|
|
JP2022537956A |
Disclosed is a method for purifying LNnT (lacto-N-neotetraose) from a fermentation broth, the method comprising subjecting the fermentation broth to a first membrane filtration step to provide a filtrate, The filtrate is subjected to a s...
|
|
JP7127164B2 |
To provide a technique for producing 18 F-FDG stably in high yield, even if using a large scale of [18F] fluoride ion in order to enhance the production amount of 18 F-FDG.A production method of 18 F-FDG comprises (a) separating [18F] fl...
|
|
JP7111625B2 |
The present invention provides a method for obtaining an alcohol compound from an ester compound with high purity and by easy operation.The high-purity alcohol compound can be obtained by a method comprising passing a solution containing...
|
|
JP7107502B2 |
The present invention relates to a method of producing a chitin oligomer, including subjecting chitin-containing biomass to partial hydrolysis while pulverizing the chitin-containing biomass with a pulverization apparatus in the co-prese...
|
